<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657758</url>
  </required_header>
  <id_info>
    <org_study_id>300027</org_study_id>
    <nct_id>NCT03657758</nct_id>
  </id_info>
  <brief_title>Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using Optical Coherence Tomography(OCT)[LINK IT TWO]</brief_title>
  <official_title>Lesional Evaluation of High Risk Patients With Neoatherosclerosis Treated With Rosuvastatin and Eicosapentaenoic Acid Using OCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kobe University</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kobe University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim is to evaluate the additional effect of eicosapentaenoic acid and dose up
      effect of rosuvastatin for neoatherosclerosis in coronary artery disease patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eicosapentaenoic acid and statin therapy prevents cardiovascular events. However, the impact
      of these treatment in patients with in-stent neoatherosclerosis has not been clarified.

      So, the investigators conducted LINK IT study. This study showed that eicosapentaenoic
      acid(EPA) and rosuvastatin therapy improve lipid index in patients compared with rosuvastatin
      alone therapy.

      However, it was insufficient to directly evaluate the efficacy of additional effect of EPA
      for neoatherosclerosis. Because, statin dose of two groups was different and type of stent
      was variety.

      Therefore, the investigators designed a new prospective, randomized OCT study. The OCT
      operators randomly assigned 75 patients who were detected neoatherosclerosis on follow-up OCT
      examination after implanted everolimus eluting stent to three groups; 5mg/day of rosuvastatin
      therapy (low dose statin therapy group) or 10mg/day of rosuvastatin therapy (high dose statin
      therapy group) or 10mg/day of rosuvastatin and 1800mg/day of eicosapentaenoic acid therapy
      (EPA and statin therapy group). Serial coronary angiography and OCT were performed at 9
      months after baseline OCT procedure.

      This study aim is to evaluate the additional effect of eicosapentaenoic acid and dose up
      effect of rosuvastatin for neoatherosclerosis in coronary artery disease patients by
      comparing 3 groups.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 17, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in lipid index</measure>
    <time_frame>9 months</time_frame>
    <description>mean lipid arc ✕ lipid length</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>9 months</time_frame>
    <description>Major cerebro-cardiovascular events（Nonfatal stroke, Nonfatal myocardial infarction, cardiovascular death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in minimum lumen area</measure>
    <time_frame>9 months</time_frame>
    <description>OCT parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in average neointimal thickness</measure>
    <time_frame>9 months</time_frame>
    <description>OCT parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in lipid arc</measure>
    <time_frame>9 months</time_frame>
    <description>OCT parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in lipid length</measure>
    <time_frame>9 months</time_frame>
    <description>OCT parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in thin cap fibroatheroma</measure>
    <time_frame>9 months</time_frame>
    <description>OCT parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in macrophage grade</measure>
    <time_frame>9 months</time_frame>
    <description>OCT parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in plaque volume</measure>
    <time_frame>9 months</time_frame>
    <description>Near infrared spectroscopy intravascular ultrasound(NIRS-IVUS) parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in max Lipid-core burden index</measure>
    <time_frame>9 months</time_frame>
    <description>NIRS-IVUS parameter</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>EPA and statin therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After randomization, patients with combination therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose statin therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After randomization, patients with high dose statin therapy start high dose rosuvastatin (10mg/day) for ９ months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose statin therapy group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After randomization, patients with low dose statin therapy take low dose rosuvastatin (5mg/day) for ９ months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPA and rosuvastatin</intervention_name>
    <description>To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.</description>
    <arm_group_label>EPA and statin therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose rosuvastatin</intervention_name>
    <description>To take high dose rosuvastatin (10mg/day) for ９ months.</description>
    <arm_group_label>High dose statin therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. over 20 years

          2. Patients implanted everolimus-eluting stent(EES) neoatherosccrelosis with
             neoatherosclerosis by OCT

          3. LDL is or less than 100 mg/dl after ingesting 5 mg/day of rosuvastatin

        Exclusion Criteria:

          1. Patients taking omega 3 fatty acid before randomization

          2. Patients allergic to rosuvastatin or eicosapentaenoic acid

          3. Patients with a history of hemorrhagic stroke

          4. Patients taking anti cancer agent

          5. Patients undergoing LDL apheresis

          6. Patients with severe liver disease or severe kidney disease

          7. Patients who conflict with any of the warnings or contraindications listed in the
             domestic package insert of rosuvastatin

          8. Patients who conflict with any of the warnings or contraindications listed in the
             domestic package insert of eicosapentaenoic acid

          9. Patients performed percutaneous coronary intervention with restenosis of target lesion

         10. Pregnant women or patients with possibility of Pregnancy or nursing woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hiromasa Otake, ph.D</last_name>
    <phone>+81-78-382-5846</phone>
    <email>hotake@med.kobe-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kobe University Graduate School of Medicine, Department of Cardiology</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <contact>
      <last_name>Hiromasa Otake, ph.D</last_name>
      <phone>+81-78-382-5846</phone>
      <email>hotake@med.kobe-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>September 16, 2018</last_update_submitted>
  <last_update_submitted_qc>September 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kobe University</investigator_affiliation>
    <investigator_full_name>Hiromasa Otake</investigator_full_name>
    <investigator_title>Senior Lecturer</investigator_title>
  </responsible_party>
  <keyword>eicosapentaenoic acid</keyword>
  <keyword>OCT</keyword>
  <keyword>neoatherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

